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Abstract
Introduction—Increasing clinical evidence supports the implementation of genotyping for anti-
hypertensive drug dosing and selection. Despite robust evidence gleaned from clinical trials, the 
translation of genotype guided therapy into clinical practice faces significant challenges. 
Challenges to implementation include the small effect size of individual variants and the 
polygenetic nature of antihypertensive drug response, a lack of expert consensus on dosing 
guidelines even without genetic information, and proper definition of major antihypertensive drug 
toxicities. Balancing clinical benefit with cost, while overcoming these challenges, remains 
crucial.
Areas covered—This review presents the most impactful clinical trials and cohorts which 
continue to inform and guide future investigation. Variants were selected from among those 
identified in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR), the 
Genetic Epidemiology of Responses to Antihypertensives study (GERA), the Genetics of Drug 
Responsiveness in Essential Hypertension (GENRES) study, the SOPHIA study, the Milan 
Hypertension Pharmacogenomics of hydro-chlorothiazide (MIHYPHCTZ), the Campania Salute 
Network, the International Verapamil SR Trandolapril Study (INVEST), the Nordic Diltiazem 
(NORDIL) Study, GenHAT, and others.
Expert Commentary—The polygenic nature of antihypertensive drug response is a major 
barrier to clinical implementation. Further studies examining clinical effectiveness are required to 
support broad-based implementation of genotype-based prescribing in medical practice.
Keywords
Antihypertensive; blood pressure; pharmacogenomics; implementation; precision medicine
CONTACT Arlene B. Chapman achapman1@bsd.uchicago.edu, 5841 S. Maryland Ave, Chicago, IL 60637.
ORCID
Michael T. Eadon  http://orcid.org/0000-0003-3066-2876
Arlene B. Chapman  http://orcid.org/0000-0003-4538-4565
Declaration of Interest
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or 
financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, 
honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. Peer reviewers on this 
manuscript have no relevant financial or other relationships to disclose.
HHS Public Access
Author manuscript
Expert Rev Precis Med Drug Dev. Author manuscript; available in PMC 2019 January 03.
Published in final edited form as:
Expert Rev Precis Med Drug Dev. 2018 ; 3(1): 33–47. doi:10.1080/23808993.2018.1420419.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
1. Introduction
Implementation of pharmacogenomics is underway across the developed world [1–5]. 
Thought leaders from the Clinical Pharmacogenomics Implementation Consortium (CPIC) 
and Dutch Pharmacogenomic Working Group (DPWG) continue to distill abundant 
pharmacogenomic evidence into actionable recommendations for clinicians [6,7]. Despite a 
lack of widespread adoption by payers, institutions such as universities, health systems, 
pharmacies, and private enterprises have driven pharmacogenomics into the clinical sphere 
because each finds value in implementing personalized medicine for patients.
The National Human Genome Research Institute’s ‘Implementing Genomics in Practice’ 
(IGNITE) initiative aims to incorporate genomic information into clinical care [8]. Several 
network members have succeeded in enabling genotype-guided dosing for clopidogrel, 
warfarin, antidepressants, and pain medications within their health systems [3,9,10]. 
Although the prevalence of hypertension exceeds 34% (85 million) of the U.S. adult 
population [11], implementation of genotype-guided dosing for antihypertensive agents has 
not been prioritized. The opportunity to improve control of hypertension persists, as the 
number of individuals with treatment-resistant hypertension has steadily increased to 13.7% 
of the general population and its cardiovascular consequences are significant [11].
Challenges must be overcome in order to realize personalized antihypertensive therapy. 
Given the enormous prevalence of hypertension, a propensity exists to approach 
hypertension treatment algorithms on a population-based level. Indeed, the Eighth Joint 
National Committee (JNC 8) simplified and relaxed therapy targets based on evidence 
produced from the ACCORD trial [12,13]. Many of the disease-specific blood pressure (BP) 
thresholds present in prior JNC iterations were removed. Subsequently, the SPRINT trial has 
again prompted reassessment of BP targets in individuals at high risk [14]. Based on data 
from SPRINT, tighter BP goals have been adopted by the American College of Cardiology/ 
American Heart Association Task Force [15]. In terms of agent selection, JNC 8 
recommended only four classes of first-line medications: thiazide-type diuretics, calcium 
channel blockers (CCBs), angiotensin converting enzyme inhibitors (ACEIs), and 
angiotensin receptor blockers (ARBs). Personalization was essentially limited to the 
prioritization of ACEI and ARB use in those with chronic kidney disease, and the converse 
in those older than 75 years of age and individuals of African-American (AA) descent – with 
race perhaps serving as a surrogate for genetic indicators of antihypertensive class response.
In contrast to the prevailing population-based algorithms, the Pharmacogenomics Research 
Network, International Consortium for Antihypertensive Pharmacogenomics Studies 
(ICAPS), and other contributors have generated robust evidence demonstrating the 
interaction of genotype with antihypertensive agent response [16]. The identified variants 
can be used to predict an individual’s response to a given BP medication or class. However, 
on balance, these interactions have failed to meet the evidentiary standards of CPIC. For 
most agents, expert consensus on dosing guidelines has not been achieved. Contributing 
factors include the small effect size of individual variants, population heterogeneity, 
population size, polypharmacy, a relative lack of major antihypertensive drug toxicities, 
varying clinical trial designs with relatively small patient populations, and the polygenic 
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nature of antihypertensive drug response. Overcoming nonadherence to therapy [17], great 
inter- and intra-patient BP variability [18,19], and differences in BP measurement strategies 
[20,21] may be of equal or greater importance in improving clinical effectiveness than 
genotype-guided prescribing. Provider inertia is an additional barrier due to a lack of 
familiarity with pharmacogenomics [22,23]. With an extensive arsenal of antihypertensive 
agents available, clinicians may feel they have ‘personalized’ antihypertensive therapy long 
before genotype–phenotype associations were identified. As such, the translation of 
pharmacogenomic data into hypertension therapy has been relegated until further replication 
and validation is conducted.
Nonetheless, this report seeks to evaluate relevant genomic studies of hypertension with their 
identified variants that portend the highest likelihood of clinical translation. The prevalence 
of hypertension is considerable and the associated cardiovascular consequences are severe 
[11], so the improvement in clinical effectiveness provided by pharmaco-genotyping is 
welcome and important. We now focus our attention on studies affording differential 
antihypertensive agent selection. Genomic predictors of incident hypertension fall outside 
the scope of this report. The ensuing review delineates the studies, variants, and related 
genes with the greatest evidence for clinical utility.
2. Body
A broad range of genetic variants and loci have been identified as predictors of 
hydrochlorothiazide (HCTZ) response (Table 1), beta-blocker response (Table 2), and 
response to CCBs or rennin-angiotensin system inhibitors (Table 3). Evidence for these 
associations was provided by a number of pharmacogenomic cohorts and trials including the 
Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR), the Genetic 
Epidemiology of Responses to Antihypertensives (GERA) study, the Genetics of Drug 
Responsiveness in Essential Hypertension (GENRES) study, the SOPHIA study, the Milan 
Hypertension Pharmacogenomics of hydrochlorothiazide (MIHYPHCTZ), the 
Pharmacogenomics of Hydrochlorothiazide Sardinian Study (PHSS), the Campania Salute 
Network (CSN), the International Verapamil SR Trandolapril (INVEST) Study, the Nordic 
Diltiazem (NORDIL) Study, and GenHAT. The polygenic nature of anti-hypertensive 
efficacy significantly complicates efforts to implement genetic testing for these agents in 
clinical practice. To date, a complete multigene model has not been developed to guide 
dosing or drug selection for these drugs. Further, the partial models that are available often 
do not account for environmental factors such as sodium intake or biochemical markers like 
renin activity levels. The evidence supporting these predictors is outlined below.
2.1. Pharmacogenomic Evaluation of Antihypertensive Responses
The first Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR1) study was a 
prospective cohort study which sought to evaluate genetic predictors of HCTZ and atenolol 
response in 768 subjects [24]. The Caucasian (N = 461) and AA (N = 298) populations were 
analyzed separately. After antihypertensive drug washout, subjects were initially prescribed 
either HCTZ or atenolol monotherapy for 9 weeks. The alternate drug was added if BP 
control (<120/ 70 mm Hg) was not obtained after titration of the initial drug which occurred 
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in over 90% of participants. PEAR1 compared home BP response to genotype in 37 
candidate single nucleotide polymorphisms (SNPs) which were selected from previously 
published SNPs associating with BP traits in large epidemiologic studies with tens of 
thousands of patients [25–29]. These traits included cross-sectional systolic blood pressure 
(SBP) and diastolic blood pressure (DBP), but the investigations had not specifically 
evaluated BP change in response to an antihypertensive agent.
PEAR1 assessed BP response to monotherapy after 9 weeks. At the conclusion of the study, 
no variant met Bonferroni-corrected statistical significance [30]. However, a three SNP 
model composed of rs1458038 (FGF5), rs3184504 (SH2B3), and rs4551053 (EBF1) 
explained 4.3% and 5.3% of the SBP and DBP response, respectively, to HCTZ 
monotherapy in Caucasians. None of these SNPs were similarly correlated in the AA 
population. In fact, the SNP in SH2B3 was nominally associated with HCTZ response with 
the opposite direction of effect in AAs.
A second model of HCTZ response was facetted by uniting metabolomics and genomics 
approaches. Three novel variants, rs2727563 in PRKAG2, rs12604940 in DCC, and 
rs13262930 in EPHX2 were uncovered in a genome-wide analysis of the Caucasian PEAR1 
cohort, with replication in the GERA cohort (described below) [31]. The metabolomics 
profiling identified 13 molecules associated with HCTZ monotherapy SBP and DBP 
responses, which were enriched for interaction with netrin signaling. Three SNPs in the 
model were selected after a round of replication because of their association with the 
arachidonic acid metabolic pathway. The crafted model is additive; individuals with only 1 
BP lowering allele had an average change in SBP and change in DBP of −1.5 and 1.2 
mmHg, respectively. In contrast, individuals with 6 BP lowering alleles had more 
remarkable reductions in SBP and DBP at −16.3 and −10.4 mmHg, respectively. The model 
was able to account for 11–12% of the variability in HCTZ BP response. Although both the 
FGF5/SH2B3/EBF1 and the PRKAG2/DCC/EPHX2 models show promise, a combined six-
gene model evaluating the independent contribution of all of these variants has yet to be 
reconciled.
Analogous to the HCTZ models, PEAR1 sought to establish predictive model of atenolol 
monotherapy response in Caucasians. A four SNP model was derived and is listed in Table 
2. rs1458038 in FGF5 is common to both the atenolol and HCTZ models, but with the C 
allele favoring atenolol efficacy and the T allele associated with HCTZ response. This SNP 
may prove to be a useful marker in BP agent selection. Again, these variants failed to 
replicate in the AA population. The authors concluded that there was insufficient evidence to 
suggest the genetic scores for either atenolol or HCTZ BP lowering alleles in Caucasians 
were associated with BP response in AAs – even when index SNPs were evaluated in 
flanking regions of the initial candidate variants. While PEAR1 was underpowered to 
identify a single variant strongly predictive of BP response, important insights were gleaned 
into the pharmacology of these drugs. When analyzed in conjunction with other BP response 
studies, additional associations have been identified which are discussed below.
To demonstrate the importance and the power of combining study cohorts, the PEAR1 study 
participants were analyzed in conjunction with the GENRES and INVEST cohorts 
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(described below). Although not part of the above model, variants in PTPRD were found to 
be significantly associated with atenolol monotherapy response, with the opposite direction 
of effect noted for HCTZ [32]. Using a genome-wide association study (GWAS) analysis, 
several SNPs near PTPRD correlated with BP response to atenolol and HCTZ therapy. The 
PTPRD gene encodes for protein tyrosine phosphatase receptor D which is important in 
malignant glioma. Two SNPs, rs12346562 and rs1104514, are located upstream of PTPRD 
gene on chromosome 9p23 and were associated with favorable DBP to atenolol and 
unfavorable DBP response to HCTZ in Caucasians. A different SNP, rs10739150, was 
located downstream of the PTPRD gene on chromosome 9p23 and was associated with 
favorable DBP to atenolol in the AA population. Finally, two additional SNPs, rs4742610 
and rs324498, located in intron of PTPRD gene were associated with resistant hypertension 
in patients with coronary artery disease. Since the SNPs near the PTPRD gene are predictors 
of the responses to atenolol and HCTZ with the opposite directional effects, these mutations 
could prove important in tailoring initial antihypertensive therapy, much like rs1458038 in 
FGF5.
The second iteration of the Pharmacogenomic Evaluation of Antihypertensive Responses 
(PEAR2) study assessed class effects of thiazides and B-blockers and studied chlorthalidone 
and metoprolol response in 457 AAs and Caucasians. CYP2D6 metabolizer status was 
identified as a predictor of metoprolol response [33]. This drug–gene pair now has formal 
allele-based dosing recommendations outlined by the DPWG. Subjects receiving 
chlorthalidone in PEAR2 served as a replication cohort for PEAR1 to help identify an 
expression quantitative trait locus, rs10995, near the gene vasodilator-stimulated 
phosphoprotein (VASP). rs10995 was associated with improved systolic and diastolic BP 
response, as well as VASP mRNA expression [34].
In a combined meta-analysis of the first PEAR1 and PEAR2 cohorts, the association of β-
blocker BP response with genotype was investigated in the AA population [35]. A total of 
459 individuals (150 treated with atenolol alone, 168 treated with metoprolol alone, and 141 
treated with atenolol and HCTZ) were included in the analysis. The variant rs201279313, 
characterized by the deletion of a TTA in the intronic region of SLC25A31, was associated 
with favorable DBP response to atenolol at a Bonferroni-corrected significance in the meta-
analysis. The SLC25A31 gene encodes a membrane transporter involved in the exchange of 
ADP and ATP across mitochondrial membranes which maintains mitochondrial membrane 
potential.
A second associated variant, rs11313667, is characterized by an insertion/deletion variant 
(C/−) in the intronic region ofleucine rich repeat containing 15 (LRRC15) gene. This SNP 
was associated with favorable SBP response in the AA population. It is important to note 
that platelet glycoprotein 5 present in the intronic region of the LRRC15 gene is associated 
with thrombosis and is elevated in hypertensive patients. In the β-blocker monotherapy 
group, a third SNP variant, rs1367094 present in the intronic region of the gene ZMAT4, 
was also associated with better DBP response at genome-wide significance. The effect size 
of the three variants was robust with per allele β values of −4.42 (rs201279313), −3.65 
(rs11313667), and −5.34 (rs1367094) mmHg. The SNPs discovered in this genomic wide 
meta-analysis warrant further investigation.
Eadon et al. Page 5
Expert Rev Precis Med Drug Dev. Author manuscript; available in PMC 2019 January 03.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
2.2. Genetic Epidemiology of Responses to Antihypertensives
The Genetic Epidemiology of Responses to Antihypertensives (GERA1 and GERA2) 
studies were the earliest pharmacogenetics study in antihypertensive agents and are a set of 
multi-ethnic prospective cohort studies examining the interindividual variability of response 
to antihypertensive agents [36,37]. After a 4 week washout, GERA1 evaluated response to 4 
weeks of HCTZ monotherapy in 505 individuals (280 Caucasian and 225 AA). GERA2 
assessed candesartan monotherapy response in 439 individuals of White and AA descent. 
The GERA cohorts have been employed in both discovery and replication analyses. Since 
many of the primary cohort studies involved multiple drugs or subjects from multiple racial 
backgrounds, pooling these studies has proven essential for increasing the sample size to 
enable discovery and improve generalizability of any identified variants.
For example, in a meta-analysis of over one million variants in the GERA1 and PEAR study 
cohorts, two variants were identified in HCTZ-exposed Caucasians at nearly genome-wide 
significance [38]. The two cohorts had similar demographics except that the PEAR enrollees 
were older and had higher pretreatment BPs. However, GERA1 assessed BP in a clinical 
research center, as opposed to the home BP responses measured in PEAR. The most 
significant association with HCTZ BP response was rs16960228, an intronic SNP located in 
PRKCA (encoding protein kinase Cα) which met genome-wide significance. This drug–
gene interaction was replicated in the GENRES and NORDIL studies, but did not reach 
significance in the MIHYPHCTZ study (trials described below). A second variant, 
rs2273359 near the GNAS-EDN3 gene regions, was nearly genome-wide significant. The 
association was replicated in the NORDIL study, but genetic data were unavailable for this 
variant in the GENRES and MIHYPHCTZ studies.
In AAs, the strongest signal identified for HCTZ response was found in YEATS4 (YEATS 
domain containing 4) related to rs7297610 [39]. This SNP was independently associated 
with DBP response in both the GERA1 and PEAR 1 cohorts. rs7297610 belongs to a 
haplotype consisting of two additional variants on chromosome 12 – rs317689 near LYZ 
(lysozyme) and rs315135 near FRS2 (fibroblast growth receptor substrate 2). The variant 
rs7297610 was found to be an expression quantitative trait locus of YEATS4, as baseline 
leukocyte mRNA expression varied across genotypes [40]. Expression of YEATS4 was 
reduced post-treatment in those with the CC genotype, providing mechanistic insight into 
the relevance of this variant.
The GERA2 study identified genes relevant to angiotensin II receptor blockade. One sub-
investigation identified 273 polymorphisms which predicted candesartan response, but held 
the opposite direction of effect for associations with HCTZ response [41]. The SNP 
rs11020821 near FUT4 (fucosyltransferase 4) was the most highly associated variant in 
Caucasians. A second SNP near FUT4, rs16924603, was nominally significant and 
maintained the same direction of effect in AAs. These variants may prove important in the 
selection of a diuretic or angiotensin II receptor blocker as initial antihypertensive therapy.
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2.3. Genetics of Drug Responsiveness in Essential Hypertension and Losartan 
Intervention For Endpoint Reduction in Hypertension
The GENRES study was a single center, placebo-controlled crossover study. Subjects 
included 228 Finnish men who received monotherapy of amlodipine, bisoprolol, HCTZ, or 
losartan in a sequential, but randomized order [42]. The study differed from PEAR and 
GERA in that neither home nor office BP was measured; instead, 24 h ambulatory BP 
monitoring was employed. The GENRES study importantly identified the missense variant 
rs3814995 in nephrin (NPHS1), which is enriched in the Finnish population associated with 
losartan response [43]. This variant was first replicated in the GERA2 and SOPHIA cohorts, 
and later in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, 
an additional Finnish cohort study (including men and women) which examined atenolol and 
losartan response in 927 subjects [44]. As opposed to GENRES, LIFE did not include an a 
priori pharmacogenomic outcome and this information was retrospectively acquired.
By co-examining the bisoprolol arm of the GENRES study with the atenolol arm of LIFE, 
rs2514036, a SNP in ACY3, was found associated with beta-blocker response. However, 
rs2514036 was not found to be predictive of atenolol response in the PEAR cohort. Two 
additional HCTZ response SNPs were uncovered near the ALDH1A3 (rs3825926) and 
CLIC5 (rs321329) genes, which maintained the same direction of effect in the PEAR and 
GERA1 cohorts.
2.4. The Italian cohorts
Four Italian studies have contributed considerable evidence for novel pharmacogenomic 
predictors of BP response: SOPHIA, the PHSS, the MIHYPHCTZ, and the CSN. The 
SOPHIA study specifically assessed losartan response in 372 hypertensive individuals. The 
study initially enrolled 722 hypertensive subjects with a systolic BP between 140 and 179 
mmHg and DBP between 90 and 109 mmHg [45]. Clinic visit BP response was utilized as 
the primary outcome after 4 weeks of losartan therapy. A number of issues affected the 
sample size in this investigation. For example, 25.3% of the cohort had normalization of 
their BP during an 8-week run-in period which required enrollees to meet dietary sodium 
and potassium restrictions. These subjects, as well as those with prior BP treatment (N = 
106), were excluded from the final analysis. Finally, the genotyping of 124 individuals failed 
to meet quality control. In the 372 remaining individuals, four SNPs (rs10752271, 
rs10906202, rs4747995, and rs10737061) in the CAMK1D gene were significantly 
associated with losartan SBP response. The gene is relevant to the aldosterone synthesis 
pathway. An intronic SNP of CAMK1D, rs10752271, reached Bonferroni significance and 
was replicated in the GENRES cohort. Whether this variant can be extrapolated as a 
predictor of response to other ARBs remains to be seen since the SNP was not associated 
with candesartan response in the GERA2 study.
Two Italian cohorts evaluated HCTZ response in individuals without prior treatment. The 
MIHYPHCTZ enrolled 142 newly diagnosed individuals with hypertension and the PHSS 
contributed an additional 343 individuals who had not undergone prior treatment for 
hypertension [46]. All participants were Caucasian with an office SBP > 140 mmHg and a 
DBP > 90 mmHg (MIHYPHCTZ allowed either SBP or DBP as entrant criteria). Both 
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studies maintained similar protocols. The MIHYPHCTZ study required a 4-week run-in 
period to standardize sodium and potassium intake, followed by an 8-week total treatment 
period. This interventional period consisted of 12.5 mg daily of HCTZ for 4 weeks and then 
25 mg daily of HCTZ for the final 4 weeks. The PHSS study used an 8-week run-in period, 
followed by an 8-week intervention trial of 25 mg daily of HCTZ without titration. Subjects 
in the PHSS cohort were older with higher BMIs and pretreatment SBPs. The GENRES, 
GERA1, NORDIL, and CSN served as replication cohorts.
The GWAS in these two Italian cohorts revealed six variants predictive of SBP response and 
five variants predictive of DBP. No SNPs were significant for both phenotypes. The most 
highly associated variants with SBP response were found in the introns of two genes, TET2 
or Tet methylcytosine dioxygenase 2 (rs12505746) and CSMD1 or CUB and Sushi multiple 
domains protein 1 (rs7387065 and rs11993031). Two SNPs, rs12505746 in TET2 and 
rs7387065 in CSMD1, were replicated in the GENRES cohort, but not in the GERA1, 
NORDIL, PEAR, or CSN groups. Both genes appear to have plausible mechanisms as TET2 
is a mediator of αENaC gene transcription in the renal collecting duct and CSMD1 is a 
member of the vacuolar-protein-sorting-13 family that has been associated with peripheral 
artery disease, metabolic syndrome, and risk of hypertension. One SNP identified in 
MIHYPHCTZ and PHSS, rs9590353 in UGGT2, was associated with HCTZ DBP response 
and was replicated in the CSN cohort. UGGT2 encodes a glycoprotein without a clear 
mechanistic role in hypertension.
The CSN is an Italian network consisting of thousands of individuals with hypertension [47]. 
These individuals are followed longitudinally by general practitioners near Naples. The 
network has evaluated the interaction of hypertension with renal function [48], obesity [49], 
left ventricular hypertrophy [50], and many other relevant phenotypes. This cohort has 
contributed important data detailing the role of a Gln27Glu variant (rs1042714) in the Beta2-
adrenergic receptor ADRB2 gene that mediates differential effects on left ventricular 
hypertrophy in those treated with atenolol [51]. The authors conclude that individuals with 
the Glu27 allele are more likely to benefit from enalapril therapy as opposed to atenolol. Of 
note, the opposite conclusion was reached in an Australian cohort where Gln27 
homozygotes showed less improvement in LVH in response to carvedilol [52].
2.5. International Verapamil SR Trandolapril Study
The INVEST Study is a multinational, open label study of 22,576 patients with hypertension 
and coronary artery disease [53]. The study aimed to compare morbidity and mortality 
outcomes in individuals randomized to receive verapamil or atenolol. Subjects were co-
treated with trandolapril and/or HCTZ to achieve adequate BP control. The study concluded 
that the calcium antagonism strategy was as effective as the β-blockade strategy in achieving 
BP goals and preventing adverse events. A subset of individuals was genotyped as part of the 
INVEST-GENES study, enabling a number of important BP response variants to be 
uncovered. Many of the studies discussed in detail above were specifically developed with a 
primary endpoint of BP response; in contrast, INVEST was different as its primary outcome 
was related to cardiovascular events including all-cause death, nonfatal MI, and nonfatal 
stroke.
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Since the study involved a CCB arm, it follows logically that several of the genes uncovered 
in INVEST are related to calcium transport or sensitivity. One such gene, KCNMB1 [54], 
was relevant for verapamil response in 5979 INVEST patients with White, Black, or 
Hispanic ancestries. KCNMB1 encodes the β1 subunit of the BK channel. Decreased 
function of this protein is associated with decreased calcium sensitivity, elevated BP, and 
cardiac hypertrophy. Two nonsynonymous polymorphisms in the KCNMB1 gene, Glu65Lys 
(rs11739136) and Val110Leu (rs2301149), contribute to the inter-patient variability in 
verapamil BP response. Lys65 variant carriers achieved BP targets faster than individuals 
who were homozygous for Glu65. The Leu110 allele correlated with protection from 
nonfatal myocardial infarction in patients treated with verapamil, but not those treated with 
atenolol.
Mirroring these results, important variants in the calcium channels themselves have been 
identified which may aid in the differential selection of a CCB or β-blocker. The variants 
tested were uncovered through candidate association studies, not genome-wide tests. 
CACNA1C encodes the alpha1c-subunit of the L-type calcium channel. In a candidate SNP 
nested case-control study, eight SNPs in CACNA1C were screened for an interaction 
between treatment effect of verapamil or atenolol with the primary outcomes of death, 
myocardial infarction, and stroke. Among those randomized to verapamil SR treatment, 
rs1051375 allele status correlated strongly with outcome. The AA genotype was associated 
with a reduction in the primary outcome (odds ratio 0.54, 95% confidence interval or CI 
0.32–0.92), while the GG genotype was associated with an increased risk of the composite 
primary outcome in those taking verapamil (odds ratio 4.59 95% CI 1.67–12.67) [55]. A 
second calcium channel, CACNB2 encoding the regulatory β2 subunit of the voltage-gated 
calcium channel, was associated with cardiovascular outcomes in individuals randomized to 
the verapamil arm [56]. The GG genotype of a promoter SNP (rs2357928) was associated 
with an increased risk of the primary outcomes in Whites, Blacks, and Hispanics in the 
verapamil arm as compared to the atenolol arm. A second SNP, rs11014166, was also 
similarly associated with outcomes in those of Hispanic ancestry as compared to Whites or 
Blacks. CACNA1C and CACNB2 remain mechanistically plausible genes that may aid in 
the selection of a CCB or beta-blocker.
The large sample size of INVEST-GENES facilitated the replication of commonly studied 
variants. For example, the influence of ADRB1 on hypertension and β-blocker response is 
well-documented, but inconsistent [57–61]. In INVEST, the Ser49-Arg389 ADRB1 
haplotype was associated with a significant mortality risk (odds ratio 3.66, 95% CI 1.68–
7.99) – whether 1 or 2 alleles were present [62]. This haplotype consists of a two SNP 
model: rs1801253 (Arg389Gly) and rs1801252 (Ser49Gly). The mortality risk was more 
pronounced in individuals treated with verapamil and nonsignificant in those individuals 
receiving atenolol. This finding would suggest that those with the Ser49-Arg389 should 
preferentially receive β-blocker therapy as it attenuates the risk mortality risk of the Ser49-
Arg389 ADRB1 haplotype. INVEST did not necessarily conclude the converse, i.e. that 
Gly49 individuals should preferentially receive CCB therapy. However, this 
recommendation would be corroborated by recent results from the Secondary Prevention of 
Small Subcortical Strokes (SPS3) trial, in which individuals with the ADRB1 Gly49 allele 
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who were treated with atenolol were at higher risk for major adverse cardiovascular events 
(hazard ratio 2.03; 95% CI 1.20–3.45) [63].
Of note, additional variants relevant to adrenergic signal transduction have been assessed. 
Polymorphisms in G protein–coupled receptor kinase 4 (GRK4) interrupt adrenergic 
signaling by leading to phosphorylation of the adrenoreceptors and inhibition of cyclic 
adenosine monophosphate production. GRK4 polymorphisms were identified in the PEAR 
and INVEST cohorts which both impact atenolol mediated BP reduction and cardiovascular 
outcomes [64].
While the INVEST cohort reinforced the association of the ADRB1 haplotype with β-
blocker response phenotypes, the study had the opposite effect on another well-chronicled 
variant, rs4961 in the α-adducin gene (ADD1). The T allele of this SNP is a 
nonsynonymous Gly460Trp mutation in ADD1. It has been associated with salt sensitivity, 
conferring increased diuretic efficacy in some studies, but not others [65–68]. A meta-
analysis of four studies and more than 1000 patients ultimately found a small but significant 
effect of the GG genotype on increased HCTZ BP response [69]. However, the results of 
INVEST suggest the T allele is associated with increased cardiovascular risk, but not HCTZ 
response as measured by either 1) DBP change or 2) total number of antihypertensive agents 
required for BP control [70].
To develop clinically useful recommendations from a vast quantity of genetic data – 
facilitating selection of either β-blocker or CCB therapy – the INVEST group built a genetic 
risk score model [71]. The most highly associated nonsynonymous SNPs in the White and 
Hispanic ethnic groups were tested and later validated in the NORDIL study. Three variants 
were selected for inclusion in the model: rs16982743 in SIGLEC12, rs893184 in A1BG, and 
rs4525 in F5. A genetic risk score ranging from 0 to 3 is assigned based on the number of 
variant alleles present with one point applied for each genotype that confers increased risk in 
the verapamil arm over the atenolol arm. In individuals with a risk score of 0 or 1, CCB 
therapy was associated with lower odds of meeting the cardiovascular endpoint (odds ratio 
0.60, 95% CI 0.42–0.86), while those at higher risk with a score of 2 or 3 were more likely 
to meet a cardiovascular endpoint higher risk (odds ratio 1.31, 95% CI 1.08–1.59) on 
verapamil and should receive a β-blocker instead.
2.6. Nordic Diltiazem
The NORDIL Study is a prospective, randomized study which enrolled over 10,000 subjects 
aged 50–74 in Norway and Sweden [72]. The cohort was composed of individuals with an 
initial diastolic BP exceeding 100 mmHg. Individuals were randomized to receive diltiazem, 
a diuretic, a β-blocker, or both a diuretic and a β-blocker. The study concluded that diltiazem 
was as effective as diuretics, beta-blockers, or both in preventing cardiovascular adverse 
events. An additional outcome of the study was the identification of rs13333226, a SNP in 
the uromodulin gene (UMOD) [73]. While this SNP was not associated with response to an 
antihypertensive agent, it was independently associated with a risk of hypertension and 
reduced urinary uromodulin excretion. The variant’s renal etiology provides a plausible 
mechanism for mediating sodium homeostasis.
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NORDIL contributed a couple of very important pharmacogenomic predictors of drug 
response. First, in a sub-study of 1990 diltiazem treated individuals, genotyping was 
completed for rs12946454, an intronic SNP of PLCD3. PLCD3 encodes a Phospholipase C 
enzyme, essential for calcium release in smooth muscle and maintaining vascular tone. The 
T allele of PLCD3 was associated with both increased systolic and diastolic BP response to 
diltiazem [74].
A second major contribution of the NORDIL study was to help identify a polymorphism in 
NEDD4L (the neural precursor cell–expressed developmentally downregulated 4-like) gene 
as a mediator of HCTZ response [75]. This SNP leads to alternative splicing and varying 
expression of the C2 domain in its host gene and related protein [76]. NEDD4-2 assists in 
the regulation of cell surface expression of the epithelial sodium channel (ENaC) in the 
principal cell of the collecting duct. The G allele of this SNP is associated with higher ENaC 
expression and higher baseline BP. This allele also predicted greater response to HCTZ and 
atenolol in the NORDIL study, without an effect on diltiazem efficacy, a finding that was 
replicated in both the PEAR and INVEST studies [77].
2.7. GenHAT
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial 
(ALLHAT) was a large study of over 40,000 individuals that reached completion in 2002. 
The study randomized patients aged 55 or older with at least one cardiovascular risk factor 
to chlorothalidone, atenolol, doxazosin, lisinopril, or amlodipine therapy. BP response and 
cardiovascular outcomes were assessed. As an ancillary study to ALLHAT, GenHAT 
included 39,114 individuals and examined several candidate hypertension-related genes to 
determine if variants in the six genes interacted with antihypertensive drug response.
The ACE gene regulates the renin-angiotensin system and promotes conversion of 
angiotensin I to angiotensin II. Previous studies had identified an interaction between ACE-
inhibitor response and the insertion/deletion (I/D) polymorphism in the ACE gene 
(rs1799752) that accounts for variation in circulating levels of the angiotensin converting 
enzyme. GenHAT rather definitively showed that the DD genotype does not influence BP 
reduction or cardiovascular outcomes in patients on ACE-inhibitor therapy, as compared to 
the I/D and II alleles [78]. Although the investigators noticed differences in the prevalence of 
myocardial infarction and left ventricular hypertrophy, the rates of death during 5-year 
follow-up did not differ for the various ACE I/D genotypes. Some of the reasons for the 
observed difference in BP independent effects in ACE I/D genotype groups might be related 
to variation in circulating ACE levels. Although the ACE DD genotype was not associated 
with ACE-inhibitor response, an additional meta-analysis did find a small but significant 
association with HCTZ response [69].
GenHAT is one of the larger genetic studies of hypertension. Its cohort was sufficient to 
enable primary discovery in the AA population. A sub-study assessed the contribution of 
genetics to interindividual variability in response to chlorothalidone, doxazosin, lisinopril, 
and amlodipine in AAs. Thirty-five candidate genes involved in the regulation of salt-water 
balance, the renin-angiotensin system, coagulation, and tissue modeling were interrogated in 
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1131 participants to determine BP response to each medication [79]. No variants reached 
Bonferroni-corrected significance.
Despite this, several variants were identified at suggestive levels of significance which can 
differentiate response to the various BP agent pairings. For example, SNPs in AGTR1 
(rs275653), F7 (rs6046), F13 (rs5985), MMP3 (rs3025058), and REN (rs6681776) were able 
to assist in distinguishing predicted chlorthalidone efficacy from amlodipine or doxazosin. 
Variants in AGT (rs5051), F7 (rs762637), and REN (rs6681776) were useful in predicting 
lisinopril utility over that of chlorthalidone. It is interesting to note that the F7 and MMP3 
genes were associated with both cardiovascular outcomes and BP response to medications.
2.8. International Consortium for Antihypertensive Pharmacogenomics Studies
The ICAPS (http://icaps-htn.org) is a multinational collaboration of at least 29 cohorts with 
over 300,000 participants. All of the studies and trials described above are included among 
its associated groups. ICAPS states its goal is to advance pharmacogenomic discovery and 
find definitive evidence to inform the use of genetic information to guide antihypertensive 
treatment decisions.
The power of this collaborative approach is illustrated in a recent meta-analysis of HCTZ BP 
response [80]. This study included individuals from the GENRES, GERA1, MIHYPHCTZ, 
NORDIL, PEAR1, and PHSS studies. Caucasians were used as the discovery cohort and the 
AA population was examined for replication. The meta-analysis identified two regulatory 
regions GJA1 (Gap Junction protein Alpha 1 gene) and FOXA1 (Forkhead box A1 gene) 
using a GWAS. GJA1 was associated with SBP response to thiazides in the caucasian 
population (rs11750990). GJA1 encodes for Connexin-43, a gap junction protein, which is 
present in myocardial smooth muscles and regulates cell-to-cell communication, elasticity 
and contractibility of vascular wall. In the replication cohort, a similar association was found 
in a second GJA1 variant, rs10499113, in the AA population.
The second locus near FOXA1 was associated with DBP response to HCTZ in both 
Caucasians (rs177848) and AAs (rs177852). FOXA1 is expressed in the collecting duct of 
the kidney and it appears to be a transcription factor, binding to the promoter regions of the 
vasopression receptor, Na+-K+ ATPase, and E-cadherin genes. Although none of the four 
SNPs in GJA1 and FOXA1 met genome-wide significance, all of the associations were 
suggestive. Adjunctively, the investigators performed a functional GWAS, using a gene-
expression-based filtering of the variants. In the meta-analysis approach, the HSD3B1 gene 
(Hydroxyl-delta-5-steroid-dehydrogenase, 3 beta and steroid delta-isomerase 1) was 
identified and found to influence BP response to thiazides in the Caucasian population. 
HSD3B1 is associated with aldosterone and ouabain synthesis; genetic variation in this gene 
has been associated with BP variation. The three gene loci that were identified influence the 
BP response to thiazide diuretics. Future research should be focused on reconciling these 
associations with the many other predictors of thiazide response, building the most complete 
model possible.
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2.9. Pharmacogenomic studies in Asian cohorts
A number of excellent cohort studies have examined variants predictive of antihypertensive 
response in Asian populations. In a Chinese prospective cohort called the Chinese 
Community-Based Comprehensive Prevention and Control of Hypertension project, 
candidate gene variants were assessed in an analysis of 1447 individuals. A SNP (rs7079) in 
AGT was found to be nominally associated with DBP reduction during benazepril therapy 
[81]. In a smaller cohort of 265 Japanese individuals (part of the HOMED-BP-GENE study) 
six SNPs were identified at nominal significance as associated with BP response of CCBs, 
ACE-inhibitors, and angiotensin II receptor blockers [82]. It is well known that amlodipine 
is metabolized by the CYP3A4 and CYP3A5 enzymes. In a study of hypertensive Chinese 
patients after renal transplantation, significant associations were found that the efficacy of 
amlodipine in CYP3A5*3 homozygotes was significantly higher than that in patients with 
other CYP3A5 genotypes [83].
2.10. Biologically attractive variants
The associations discussed in the preceding sections have been uncovered through either 
carefully selected candidate variant studies or unbiased whole genome approaches. Biologic 
plausibility is readily understood for candidate variants in genes of BP pathways such as the 
renin-angiotensin-aldosterone system, adrenergic signaling, or sodium reabsorption 
pathways. For example, rs4149601 in NEDD4L impacts expression of ENaC in the 
collecting duct, driving sodium reabsorption. The locus for this SNP was first found in a 
linkage analysis and then the actual SNP was confirmed to impact BP in additional cohorts 
[76,84,85]. Subsequently, the G allele of this SNP was found to be associated with higher 
ENaC expression, higher baseline BP, and improved response to diuretics [75]. Although the 
NORDIL study identified an association between the G allele of rs4149601 and diuretic 
response, the effect size was greatest among the 258 individuals on a potassium-sparing 
diuretic (β: 9.0 ± 3.4 mmHg in the dominant model) such as amiloride which directly blocks 
ENaC – speaking to the biologic relevance of this variant.
Other biologically attractive candidate variants include the GenHAT variants in 
angiotensinogen (rs5051) and renin (rs6681776). These SNPs offer credible targets for 
discrimination between lisinopril and chlorthalidone efficacy [79], possibly acting as 
surrogates for renin activity. Analogously, the CACNA1C (encoding a subunit of the L-type 
calcium channel) variant from INVEST (rs1051375) aids in differential selection of a β-
blocker or CCB [55]. Further corroborating their role, variants in CACNA1C and AGT were 
also discovered to predict incident hypertension in the Cohorts for Heart and Aging 
Research in Genomic Epidemiology Consortium [26]. These studies indicate that several 
gene loci that predict the development of hypertension and cardiovascular outcomes also 
influence the response to anti-hypertensive medications.
In contrast, rs7297610 in YEATS4 is a less obvious biologically attractive candidate. 
YEATS4 is a transcription factor that is involved in acetylation of nucleosomal histone 
proteins. The SNP was initially identified as part of a GWAS [39]. In order to enhance the 
plausibility of its relationship to HCTZ response, the investigators showed that the variant 
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allele impacted expression of its host gene and that expression was associated with a HCTZ 
response phenotype [40].
Ten Genome wide association studies have revealed a great deal about the underlying 
biology of hypertension. To this end, a number of variants and genes identified in 10 of the 
largest incident hypertension GWAS trials [25–29,86–90] were cross-referenced with the 
pharmacogenomic predictors discussed above. Since the variants from genes discovered in 
the disease association studies served as candidates for some of the pharmacogenomic 
studies, overlap did exist. As discussed above, SNPs from FGF5, SH2B3, and EBF1 were 
associated with both HCTZ response in PEAR and incident hypertension in the CHARGE 
consortium [29,30]. SNPs in PLCD3, CACNA1C, and ADRB1 were similarly found to 
impact incident BP in the CHARGE and Global BPgen Consortiums [26,29]. The majority 
of variants and genes that overlap with pharmacogenomic variants were identified from 
disease association studies published prior to 2015. It is possible that the variants in newer 
GWAS studies [86–90] will ultimately associate with antihypertensive drug efficacy, but 
these studies have not been conducted yet.
Pharmacogenomic Predictors of Toxicity—Much of the discussion above has 
centered on variants associated with BP drug efficacy; however, variants associated with 
pharmacogenomic predictors of toxicity have also been uncovered – with the strongest 
evidence found in the HCTZ studies. For example, the GERA and PEAR studies have 
identified genetic variation underlying HCTZ-induced hypertriglyceridemia, elevated uric 
acid levels, and hypokalemia. Two variants in NELL1, rs12279250 and rs4319515, were 
found to be associated with a significant change in fasting serum triglyceride levels in AAs 
[91]. In both AAs and Caucasians, several loci were identified that predicted elevations in 
uric acid [92]. In the PEAR and GERA cohorts, two SNPs near the HEME binding protein 1 
gene (rs10845697) and the Mitoferrin-1 gene (rs11135740) were found to be significant 
predictors of hypokalemia in a mixed analysis of Caucasians and AAs [93].
Variants have also been identified that are predictive of HCTZ-induced new-onset diabetes 
or elevated fasting plasma glucose in the INVEST-GENES study. In the INVEST and PEAR 
cohorts, variants predictive of elevating fasting blood sugar or new-onset diabetes have been 
investigated. Studies have identified SNPs associated with the development of HCTZ-
induced new-onset diabetes [94–96]. A risk allele, rs7917983 in TCF7L2, yielded an odds 
ratio of 1.53 (95% CI 1.04–2.25) for the development of diabetes in response to HCTZ use. 
The opposite allele held a protective effect, as it decreased the odds of diabetes development 
to 0.48 (95% CI 0.27–0.86) in individuals never treated with HCTZ [94]. In a candidate 
association study, KCNJ1 was assessed because of the suspected relationship between 
HCTZ-induced hypokalemia and blood sugar. KCNJ1 encodes a potassium channel which 
has been associated with changes in fasting plasma glucose in response to HCTZ treatment. 
During a combined analysis of INVEST and PEAR, over 10 SNPs were found to be 
significantly associated with new-onset diabetes during HCTZ therapy. Haplotypes were 
constructed for the AA, Hispanic, and Caucasian populations [95] which are predictive of 
diabetes development. Although the odds ratio of new-onset diabetes is above 2 when risk 
alleles are present, it is clear a multivariant predictive model is required should this 
information be translated into clinical practice.
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3. Conclusion
In summary, we present an overview of the most impactful pharmacogenomic studies of 
antihypertensive agent response. A prodigious wealth of information has been derived from 
the efforts of those involved in PEAR, GERA, GENRES, SOPHIA, MIHYPHCTZ, the 
CSN, INVEST, NORDIL, GenHAT, ICAPS, and others. This knowledge has increased our 
appreciation of the underlying pathophysiology of hypertension as well as the 
pharmacodynamics of commonly used drugs. High evidence variants relevant to HCTZ, β-
blockade, calcium channel antagonism, and renin-angiotensin antagonism are presented and 
summarized.
It is most likely that polygenic models will be needed to inform clinical behavior in an 
additive fashion. A sophisticated computational analysis will be required to build clinical 
recommendation sets from the polygenic architecture that has been discovered. As we move 
into the next phase of pharmacogenomic discovery and application, randomized controlled 
trials should, to the extent possible, standardize genotyping platforms, define precise 
phenotypes and outcomes, and employ common BP measurement techniques. Clinical 
effectiveness trials may be entertained which examine panels of genes in a real-world setting 
of polypharmacy. The incredible diversity of genes and variants uncovered presents both an 
obstacle and an opportunity for future clinical translation.
4. Expert commentary
The promise of discovery using GWA Studies for complex medical disorders has been 
significantly underappreciated. As this review shows, multiple SNPs in genes with 
biological plausibility for a role in hypertension, BP response and/ or alternatively 
cardiovascular and mortality risk have been identified. Given that only rare variants would 
have a large effect size, it is not surprising that the platforms used in the pharmacogenetics 
studies reported in this review would not capture these variants given that all required a 
minor allele frequency of > 0.05. This review substantially supports the value of multiple 
SNPs in combination providing significant measures of the interindividual variability of BP 
response to multiple classes of antihypertensive agents. In addition, although evidence for 
adverse events related to antihypertensive therapy is now forthcoming, it is highly likely that 
many more issues related to the genetic prediction of safety of antihypertensive medications 
will be coming forward.
Power and replication continue to be the biggest barriers to identifying genetic predictors of 
BP response. Combined cohorts, as mentioned in this report, are limited primarily in 
heterogeneity in study design that impacts patient characteristics, methods of pre-study 
medication withdrawal, and duration and dosing of study medication. Despite these 
differences, consistent genetic signals are emerging, which should, if they play a predictive 
role in BP response to a particular agent or class of agent. This suggests then, that despite 
heterogeneity of study populations and study design, the same answer should be obtainable.
Implementation science is now required to best take these findings forward in a way that is 
clear, easy to use and overcomes the potential clinician inertia that may be present due to 
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lack of formal education in genetics, familiarity with the available pharmacogenomic 
evidence, and a computer decision support (CDS) system which efficiently filters drug dose 
and class recommendations in the clinic. Before this translation can be realized, consensus 
guidelines will be required which delineate the variants relevant to each drug, in each 
population.
5. Five-year view
There are key barriers to implementing pharmacogenomic-based prescribing in the treatment 
of hypertension. Two notable issues include the polygenic nature of BP response and the 
relatively small contribution of any single variant to the BP response phenotype. The authors 
speculate that even advances in technology will be unable to overcome these impediments 
over the next several years. Many electronic medical record systems contain CDS to aid 
clinicians in dosing medications. The authors believe it is more likely that a clinical 
bioinformatics model of antihypertensive drug-dosing and titration will be implemented 
before a genomic model. Factors such as age, demographics, race, ethnicity, drug– drug 
interactions (DDIs), and plasma renin activity are stronger predictors of antihypertensive 
response than most of the genetic variants discussed in this review [97]. A CDS algorithm 
that incorporates these clinical predictors, DDIs, and plasma renin activity is a more cost-
effective and evidence-based approach to optimizing antihypertensive response. Additional 
implementation science studies are required to confirm if genetic variants of 
antihypertensive response add value over a clinical algorithm.
From an investigational standpoint, whole exome (or genome) sequencing is likely to 
become more common place in clinical studies of genetics. In some cases, this sequencing 
data will move into the clinical sphere as part of implementation science; however, it is more 
likely to be applied to disease prediction or pharmacogenomic prediction with large effect 
sizes. The genetic data will continue to trend toward increasing complexity and even greater 
individualization. Algorithm development will prove essential to afford rapid translation of 
polygenic data into a single, sometimes binary, clinical recommendation. The 
implementation of these algorithms will also rely upon CDS to move complex genetic 
matrices into the clinical setting. Complex risk scores will be calculated behind the scenes 
and clinicians will use these risk scores to inform their prescribing habits.
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Key issues
• Hypertension is a major risk factor for cardiovascular disease and blood 
pressure control remains sub-optimal in the United States. Treatment-resistant 
hypertension exceeds 13% of the general population. Present guidelines 
provide little guidance on personalization of antihypertensive regimens.
• Pharmacogenomic markers have been identified that predict the blood 
pressure lowering response to commonly used antihypertensive agents.
• The major trials and cohorts providing the strongest level of evidence for 
genomic predictors of hypertension drug response are described. These 
studies are quite heterogeneous in their populations, outcomes, variants 
assessed, drugs utilized, and measurement of blood pressure. As such, the 
identified variants may replicate in some, but not all studies. Genetic 
interactions with blood pressure response have failed to meet the evidentiary 
standards of the Clinical Pharmacogenomics Implementation Committee.
• Barriers persist which limit clinical translation. To date, few drugs have expert 
consensus on pharmacogenomic dosing guidelines. Further, the small effect 
size of some variants, frequent polypharmacy, and polygenic nature of 
antihypertensive drug response must be addressed and overcome in future 
studies.
• In order to accomplish clinical translation, multiple studies with large sample 
sizes, well defined populations, and standardized blood pressure phenotypes 
are required. Replication is essential. The development of multi-gene models 
and computer decision support algorithms will further assist in this endeavor.
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